Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.

International journal of hematology - 1 May 2022

Loscocco Giuseppe G, Vannucchi Alessandro M

Abstract excerpt

Classic Philadelphia-negative myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), classified as primary (PMF), or secondary to PV or ET. All MPN, regardless of the underlying driver mutation in JAK2/CALR/MPL, are invariably associated with dysregulation of JAK/STAT pathway. The discovery of JAK2V617F point mutation prompted the development of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Janus Kinases
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Signal Transduction

Share to STAT Transcription Factors

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 35352288
DOI: 10.1007/s12185-022-03335-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.PMID 35352288Read ↗

Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersSemantic proximity Read ↗

Emerging treatments for classical myeloproliferative neoplasms.Semantic proximity Read ↗

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 inhibitors for myeloproliferative neoplasms: what is next?Semantic proximity Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.Semantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.